Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALLR

ALLR - Allarity Therapeutics, Inc. Stock Price, Fair Value and News

$1.09-0.11 (-9.17%)
Market Closed

Price Targets

ALLR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLR Price Action

Last 7 days

-7.6%

Last 30 days

3.8%

Last 90 days

-22.1%

Trailing 12 Months

-24.3%

ALLR RSI Chart

ALLR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLR Valuation

Market Cap

17.2M

Price/Earnings (Trailing)

-1.13

EV/EBITDA

-1.31

Price/Free Cashflow

-1.17

MarketCap/EBT

-1.13

ALLR Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALLR Fundamentals

ALLR Earnings

Earnings (TTM)

-15.3M

Earnings Growth (Yr)

75.79%

Earnings Growth (Qtr)

-20.95%

ALLR Profitability

Return on Equity

-127.47%

Return on Assets

-73.62%

Free Cashflow Yield

-85.77%

ALLR Investor Care

Shares Dilution (1Y)

256.64%

About Allarity Therapeutics, Inc.

ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
0
 CEO
 WEBSITEallarity.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Allarity Therapeutics, Inc. Frequently Asked Questions

ALLR is the stock ticker symbol of Allarity Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Allarity Therapeutics, Inc. is 17.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALLR's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALLR is over valued or under valued. Whether Allarity Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Allarity Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLR.